hMG: Physiology and What Research Reports

hMG is an abbreviation that carries at least three unrelated meanings in the published literature, and readers who encounter the term in a peptide or hormone context are often looking at one of them without realising the others exist. Sorting them out first makes the rest of the literature readable. This page is for educational purposes only and is not medical advice; consult a licensed physician for any question about health, treatment or a specific compound.

What "hMG" Refers To in the Literature

Human Menopausal Gonadotropin: Origin and Biological Role

Human menopausal gonadotropin is a glycoprotein hormone preparation historically purified from the urine of postmenopausal women, in whom circulating gonadotropin output is high because ovarian negative feedback has fallen away. It carries both follicle-stimulating hormone (FSH) and luteinising hormone (LH) activity. In normal physiology, FSH and LH are secreted by gonadotrope cells of the anterior pituitary under pulsatile control by gonadotropin-releasing hormone from the hypothalamus; FSH drives follicular recruitment and granulosa cell function in the ovary and supports spermatogenesis in the testis, while LH drives theca cell androgen production, ovulation and Leydig cell steroidogenesis. Because these hormones are glycoproteins rather than short peptides, they appear on the edge of "peptide" discussions rather than at the centre of them.

Clinical research using hMG has largely focused on controlled ovarian stimulation and endometrial preparation. A large retrospective cohort study compared hMG stimulation with or without letrozole for endometrial preparation before frozen-thawed embryo transfer in ovulatory women and reported pregnancy and neonatal outcomes across the compared groups (PMID 31814708). The study design was observational and retrospective, which means researchers described associations between the protocols used and the outcomes recorded rather than establishing cause and effect.

High Mobility Group Proteins: A Different hMG Entirely

The high mobility group proteins were named for how quickly they migrated on polyacrylamide gels. They are abundant non-histone nuclear proteins that bind DNA and chromatin without sequence specificity in most cases, bending and loosening nucleosomal DNA so that other regulatory proteins can gain access. A 2022 review described the HMGA, HMGB and HMGN families as architectural chromatin factors and surveyed their connections to developmental biology, inflammation and malignant disease (PMID 35204819).

Their interplay with linker histones is a long-standing research theme. An earlier biochemical study examined HMG-D and histone H1 during chromatin assembly and early embryogenesis and reported that the two proteins occupied overlapping roles at different developmental stages (PMID 11473125). More recently, researchers described a long non-coding RNA designated LncRNA-HMG and reported that it promoted chemoresistance in colorectal cancer cells by repressing p53-mediated ferroptosis (PMID 39307047).

The HMG-Box Domain and the SOX Family

The HMG-box is an approximately 80-amino-acid, L-shaped, three-helix fold that binds the DNA minor groove and bends it sharply. It defines the SOX family of transcription factors, including SRY, the mammalian testis-determining factor. A functional swap study in mice assayed the HMG domains of SOX3, SOX9 and SRY in male sex determination and reported that these domains were functionally related in that assay (PMID 11105052). A bioinformatic and expression analysis of the HMG-box family reported that SOX6 was significant in the malignant progression of glioblastoma (PMID 32388501). HMG-box domains are not confined to animals: researchers characterising the Arabidopsis histone chaperone FACT reported on the role of the HMG-box domain of its SSRP1 subunit (PMID 29966609).

HMG-CoA: The Metabolic Meaning

3-hydroxy-3-methylglutaryl coenzyme A sits at a branch point in metabolism. HMG-CoA reductase converts it to mevalonate, committing carbon to the isoprenoid and sterol pathway, while HMG-CoA lyase cleaves it toward ketone body production. Structural and functional work on HMG-CoA reductase from the plant Artemisia annua characterised the enzyme computationally and described its catalytic architecture (PMID 21364776). In a fungal biotechnology study, researchers introduced an insertion mutation into HMG-CoA lyase via Agrobacterium tumefaciens-mediated transformation and reported an increased production yield of mycophenolic acid (PMID 27558440). Pharmacologically, HMG-CoA reductase inhibitors are the statin class, and a review catalogued their reported pleiotropic effects beyond cholesterol lowering (PMID 21556312).

How These Molecules Are Measured and Studied

• Recombinant expression. A 2025 protocol paper described prokaryotic expression and purification of the human Sox2 HMG domain, giving a reproducible route to isolated domain protein for binding studies (PMID 40873475).
• Structural and computational characterisation. Modelling and sequence analysis were used to describe HMG-CoA reductase architecture in a plant system (PMID 21364776).
• Expression profiling in disease cohorts. HMG-box family members were screened for association with tumour progression in glioblastoma datasets (PMID 32388501).
• Retrospective clinical cohorts. Pregnancy and neonatal endpoints were extracted from clinic records in the hMG stimulation study (PMID 31814708).
• Spontaneous adverse-event reporting. National pharmacovigilance databases were used to collate case reports for HMG-CoA reductase inhibitors (PMID 17057271).

Adverse Events and Safety Signals: What Studies Report

Safety literature differs by which hMG is meant. For the statin class, an analysis of reports submitted to the Netherlands Pharmacovigilance Centre described cases of neuropathy associated with HMG-CoA reductase inhibitors, a signal drawn from spontaneous reporting rather than from a controlled trial (PMID 17057271). The same review literature that catalogued statin pleiotropic effects also framed those effects as class properties that required further mechanistic study (PMID 21556312). For human menopausal gonadotropin, the retrospective cohort described above reported neonatal as well as pregnancy outcomes among the protocols compared (PMID 31814708). Spontaneous reports and retrospective records cannot establish incidence or causation on their own.

Limitations of the Current Literature

Much of the HMG protein work summarised here was done in cell lines, model organisms or plants, and researchers were explicit that findings in those systems do not transfer automatically to human physiology (PMID 29966609). Oncology findings such as the LncRNA-HMG chemoresistance mechanism were reported at the cell and pathway level (PMID 39307047). And the abbreviation itself remains the biggest source of confusion: a paper on "HMG" may concern a hormone preparation, a chromatin protein, a protein domain or a metabolic intermediate, and only the full term disambiguates it.

References

• Pregnancy And Neonatal Outcomes Of hMG Stimulation With Or Without Letrozole In Endometrial Preparation For Frozen-Thawed Embryo Transfer In Ovulatory Women: A Large Retrospective Cohort Study (Drug Design, Development and Therapy, 2019)
• HMG Proteins from Molecules to Disease (Biomolecules, 2022)
• HMG-D and histone H1 interplay during chromatin assembly and early embryogenesis (Journal of Biological Chemistry, 2001)
• LncRNA-HMG incites colorectal cancer cells to chemoresistance via repressing p53-mediated ferroptosis (Redox Biology, 2024)
• Related function of mouse SOX3, SOX9, and SRY HMG domains assayed by male sex determination (Genesis, 2000)
• Identification of HMG-box family establishes the significance of SOX6 in the malignant progression of glioblastoma (Aging, 2020)
• The Arabidopsis Histone Chaperone FACT: Role of the HMG-Box Domain of SSRP1 (Journal of Molecular Biology, 2018)
• Structural and functional characterization of HMG-COA reductase from Artemisia annua (Bioinformation, 2010)
• Insertion Mutation in HMG-CoA Lyase Increases the Production Yield of MPA through Agrobacterium tumefaciens-Mediated Transformation (Journal of Microbiology and Biotechnology, 2016)
• Pleiotropic effects of the HMG-CoA reductase inhibitors (International Journal of General Medicine, 2011)
• Prokaryotic Expression and Purification of the hSox2-HMG Domain (Bio-protocol, 2025)
• HMG-CoA-reductase inhibitors and neuropathy: reports to the Netherlands Pharmacovigilance Centre (Netherlands Journal of Medicine, 2006)